SNA™ Platform Technologies

Learn More

SNA™ Platform Technologies

Learn More

About Us

Exicure, formerly AuraSense Therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology.

SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics:  safe and effective delivery into cells and tissues.  SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents.  Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.

SNA™ technology originated in the lab of Professor Chad A. Mirkin at the Northwestern University International Institute for Nanotechnology.  Exicure's intellectual property portfolio includes 47 pending patent applications and 26 allowed or issued patents.  These filings impact numerous jurisdictions worldwide, and they cover a range of inventions, including fundamental nanoparticle manufacturing breakthroughs and numerous application-specific improvements.

Latest News

  • AuraSense Therapeutics Announces Publication of Preclinical Data Demonstrating Immuno-Modulation by its Proprietary Spherical Nucleic Acid Platform

    April 22, 2015go

  • C&EN News Explores Immune Modulating Capabilities of SNA Technology

    April 13, 2015go

  • Biotuesdays: In Conversation with David Giljohann

    February 10, 2015go

  • AuraSense Therapeutics Adds to Series C Financing

    February 4, 2015go

  • David Giljohann Named Among Top 40 Under 40 by Analytical Scientist

    October 29, 2014go